Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.60 |
| ▸ | PI4KA | P42356 | 12/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 12/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 12/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 12/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580610 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL667204 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8284838 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL8069211 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1370892 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2342091 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL106573 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1357265 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9074153 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119265192-A | Compound of modified nucleotide monomer and application of compound in RNAi (ribonucleic acid interference) medicament | 纳肽得(青岛)生物医药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-118834250-A | Novel delivery vehicle | 纳肽得(青岛)生物医药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118834255-A | Novel modified nucleotide and application thereof in RNAi (ribonucleic acid interference) medicament | 纳肽得(青岛)生物医药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118813612-A | Application of compound in RNAi (ribonucleic acid interference) medicament | 纳肽得(青岛)生物医药有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-117737057-A | Small nucleic acid sequence with enhanced anti-hepatitis B effect and conjugate thereof | 纳肽得(青岛)生物医药有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117363614-A | SiRNA for inhibiting expression of angiotensinogen and application thereof | 纳肽得(青岛)生物医药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117363615-A | SiRNA for inhibiting complement C5 expression and application thereof | 纳肽得(青岛)生物医药有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-01-08 | — | — | US | disclosed |
| CN-104592337-B | A kind of preparation method of 9- β-D- arabinofuranosidases glycosyl -2- fluoro adenine -5 '-phosphate | 山东新时代药业有限公司 | 2018-09-07 | — | — | CN | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | disclosed |
| CN-101099745-A | Methods and compositions for treating flaviviruses and pestiviruses | IDENIX CAYMAN LTD (VG) | 2008-01-09 | — | — | CN | disclosed |
| CN-1816338-A | Use of roscovitine for treating lymphocytic leukemia | CYCLACEL LTD (GB) | 2006-08-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | XDH, HSP90B1, HSP90AA1 | ADORA2A 249/4885ADORA1 388/4885PI4KA 2546/4885 |
| US-20120208806-A1 | Hsp90 Inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | ADORA2A 4807/4885ADORA1 4859/4885PI4KA 2194/4885 |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | XDH, HSP90B1, HSP90AA1 | ADORA2A 249/4885ADORA1 388/4885PI4KA 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.